Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
USRE47194E1 · kind E1 · reissue
0Cited by
15References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 2015 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | Apr 7, 2035 |
Classification
- Technology area (CPC —)General
Abstract
Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p I
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.